These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 31828158

  • 1. Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy.
    Asano S, Himeno T, Hayami T, Motegi M, Inoue R, Nakai-Shimoda H, Miura-Yura E, Morishita Y, Kondo M, Tsunekawa S, Kato Y, Kato K, Naruse K, Nakamura J, Kamiya H.
    J Diabetes Res; 2019; 2019():2756020. PubMed ID: 31828158
    [Abstract] [Full Text] [Related]

  • 2. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
    Matsumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V.
    J Pharmacol Sci; 2008 Jul; 107(3):231-7. PubMed ID: 18635918
    [Abstract] [Full Text] [Related]

  • 3. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K, Kohara N, Baba M, Komori T, Naito Y, Imai T, Satoh J, Yamaguchi Y, Hamatani T, Ranirestat Group.
    J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
    [Abstract] [Full Text] [Related]

  • 4. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V, Buchanan RA.
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [Abstract] [Full Text] [Related]

  • 5. Ranirestat for the management of diabetic sensorimotor polyneuropathy.
    Bril V, Hirose T, Tomioka S, Buchanan R, Ranirestat Study Group.
    Diabetes Care; 2009 Jul; 32(7):1256-60. PubMed ID: 19366965
    [Abstract] [Full Text] [Related]

  • 6. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.
    Matsumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V.
    J Pharmacol Sci; 2009 Feb; 109(2):203-10. PubMed ID: 19212096
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
    Polydefkis M, Arezzo J, Nash M, Bril V, Shaibani A, Gordon RJ, Bradshaw KL, Junor RW, Ranirestat Study Group.
    J Peripher Nerv Syst; 2015 Dec; 20(4):363-71. PubMed ID: 26313450
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of ranirestat for the treatment of diabetic neuropathy.
    Giannoukakis N.
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1051-9. PubMed ID: 24785785
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase.
    Price SA, Agthong S, Middlemas AB, Tomlinson DR.
    Diabetes; 2004 Jul; 53(7):1851-6. PubMed ID: 15220210
    [Abstract] [Full Text] [Related]

  • 15. Peripheral neuropathy in mice with neuronal nitric oxide synthase gene deficiency.
    Vareniuk I, Pacher P, Pavlov IA, Drel VR, Obrosova IG.
    Int J Mol Med; 2009 May; 23(5):571-80. PubMed ID: 19360314
    [Abstract] [Full Text] [Related]

  • 16. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.
    Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T, Fukami A, Hamada Y, Inagaki N, Seino Y, Drucker DJ, Oiso Y, Nakamura J.
    Diabetes; 2011 Sep; 60(9):2397-406. PubMed ID: 21810596
    [Abstract] [Full Text] [Related]

  • 17. Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats.
    Shimoshige Y, Minoura K, Matsuoka N, Takakura S, Mutoh S, Kamijo M.
    Brain Res; 2009 Jan 09; 1247():182-7. PubMed ID: 18992730
    [Abstract] [Full Text] [Related]

  • 18. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H, Miki T, Kyogoku I, Kawagishi T, Inaba M, Okuno Y, Nishizawa Y, Morii H.
    No To Shinkei; 1998 Sep 09; 50(9):817-20. PubMed ID: 9789304
    [Abstract] [Full Text] [Related]

  • 19. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.
    J Diabetes Complications; 1999 Sep 09; 13(3):141-50. PubMed ID: 10509874
    [Abstract] [Full Text] [Related]

  • 20. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
    Sasaki H, Naka K, Kishi Y, Furuta M, Sanke T, Mukoyama M, Nanjo K.
    Exp Neurol; 1997 Aug 09; 146(2):466-70. PubMed ID: 9270057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.